Evidence map›Paper›PMID 40304746›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

A flavonoid Ombuin ameliorates thioacetamide-mediated liver cirrhosis in vivo: biochemical, immunohistochemical, inflammatory approaches.

Khaled Abdul-Aziz Ahmed, Talal Salem Al-Qaisi, Ahmed A J Jabbar, Parween Abdul-Samad Ismail, Mohammed M Hussein M Raouf, Hanan Ibrahim Althagbi, Bassam Ali Abed Wahab, Rawaz Rizgar Hassan, Mahmood Ameen Abdulla, Ahmed Hameed Al-Dabhawi and 1 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Khaled Abdul-Aziz AhmedDepartment of Basic Dental Sciences, Faculty of Dentistry, Al-Ahliyya Amman University, Amman, 19328, Jordan.
Talal Salem Al-QaisiDepartment of Biomedical Sciences, College of Health Sciences, Abu Dhabi University, P.O. Box 59911, Abu Dhabi, United Arab Emirates.
Ahmed A J JabbarDepartment of Medical Laboratory Technology, Erbil Technical Health and Medical College, Erbil Polytechnic University, Erbil, 44001, Iraq. ahmed.abuljabbar@epu.edu.iq.
Parween Abdul-Samad IsmailDepartment of Chemistry, College of Education, Salahaddin University, 44001, Erbil, Iraq.
Mohammed M Hussein M RaoufDepartment of Biomedical Sciences, College of Science, Cihan University-Erbil, Kurdistan Region, Erbil, 44001, Iraq.
Hanan Ibrahim AlthagbiDepartment of Chemistry, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Bassam Ali Abed WahabDepartment of Physiology, Biochemistry and Pharmacology, Faculty of Vet Medicine, University of Kufa, Kufa, Iraq.
Rawaz Rizgar HassanDepartment of Medical Laboratory Science, College of Science, Knowledge University, Kirkuk Road, Erbil, 44001, Iraq.
Mahmood Ameen AbdullaDepartment of Medical Analysis, Faculty of Applied Science, Tishk International University, Erbil, Iraq.
Ahmed Hameed Al-DabhawiCollege of Nursing, University of Altoosi, Najaf, Iraq.
Musher Ismael SalehDepartment of Chemistry, Faculty of Science and Health, Koya University, Koya KOY45, Kurdistan Region, Erbil, 44001, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cirrhosis is posing a global public health concern despite improvements in early diagnosis and therapeutic innovations. The present work evaluates the acute toxicity and prophylactic effects of an O-methylated flavonoid (Ombuin) in thioacetamide (TAA)-induced liver injury in rats and its underlying mechanisms. Thirty Sprague-Dawley rats were aligned into five cages and treated for two months as follows: group A ingested orally 1% CMC + distilled water (i.p.); group B had 1% CMC + 200 mg/kg TAA i.p. (three times weekly); group C had 50 mg/kg silymarin + 200 mg/kg TAA; group D had 30 mg/kg Ombuin + TAA; group E had 60 mg/kg Ombuin + mg/kg TAA. The non-toxic effects of Ombuin were evidenced by the lack of any toxicity incidence in rats ingested with up to 500 mg/kg. The TAA inoculation provoked significant hepatic intoxication confirmed by histopathological indications, alteration of tissue architecture, cellular proliferation, endothelial injury, enlarged hepatic nucleus, cytoplasmic vacuolation, collagen deposition, and elevated necrotizing tissues. The oxidative stress and inflammation process was noticeably initiated following TAA delivery to rats evidenced by down-regulation of SOD, CAT, GPx, and IL- 10, while, up-regulating the MDA and TNF-α and IL- 6 cytokines. TAA injection stimulated cellular proliferation and apoptotic actions in injured liver tissues, indicated by increased proliferating cell nuclear antigen (PCNA) and elevated expression of Bcl- 2-associated X (Bax) proteins. Ombuin supplementation showed significant resistance against TAA-mediated hepatotoxicity, reversed those cellular alterations, and restored liver functions. These results demonstrate significant ameliorative effects of Ombuin in TAA hepatotoxic rats, which could be attributed to its anti-apoptotic, antioxidant, and anti-inflammatory potentials, making it a possible viable hepatoprotective agent for inflammatory-related hepatitis.

Indexed as

Anti-Inflammatory AgentsAntioxidantsChemical and Drug Induced Liver InjuryFlavonoidsLiver CirrhosisAnimalsApoptosisCytokinesInflammationLiverMaleOxidative StressRatsRats, Sprague-DawleyThioacetamideAnti-Inflammatory AgentsAntioxidantsCytokinesFlavonoidsThioacetamideAntioxidant enzymesHistologyLiver cirrhosisOmbuinThioacetamide

Identifiers

PMID40304746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.